Bucinnazine
| AP-237 | |
|---|---|
 | |
| Molecular structure via molpic based on CDK |
| Rotamer [] | |
|---|---|
| Conformer structure via 3Dmol.js |
| Physical properties [] | |
|---|---|
| Molecular mass | 272.4 g/mol [1] |
| Predicted LogP | 2.5 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C17H24N2O [1] |
| IUPAC name | 1-[4-(3-phenylprop-2-enyl)piperazin-1-yl]butan-1-one [1] |
| SMILES | CCCC(=O)N1CCN(CC1)CC=CC2=CC=CC=C2 [1] |
| InChI | InChI=1S/C17H24N2O/c1-2-7-17(20)19-14-12-18(13-15-19)11-6-10-16-8-4-3-5-9-16/h3-6,8-10H,2,7,11-15H2,1H3 [1] |
| InChIKey | ZQBMUHABRSEAIK-UHFFFAOYSA-N [1] |
Bucinnazine (also known as Bucinnazine, 1-Butyryl-4-cinnamylpiperazine, Dtxsid401318270, AP-237, Piperazine, 1-(1-oxobutyl)-4-(3-phenyl-2-propenyl)-, Dtxcid901449420, AP 237, 1-(1-Oxobutyl)-4-(3-phenyl-2-propenyl)piperazine, J735KL8O54 or N-Butyryl-N'-cinnamyl-piperazine) is a
Chemistry
Stereochemistry []
Bucinnazine is a racemic mixture of the enantiomers.
| Stereoisomerism |
|---|
| Stereoisomer enumberation with rdkit |
Subjective effects []
Legal status []
- United Kingdom: Bucinnazine is a PSA substance.
- United States: Bucinnazine is a Controlled Substances Act#Schedule I drugs|Schedule I substance.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 86618, Bucinnazine. Accessed April 8, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/86618